However, the question of whether those for whom antihyperglycemic therapy may not be indicated would benefit from initiation of SGLT2 inhibitors remains to be addressed (e.g., whether those at high risk of cardiovascular and kidney events following SARS-CoV-2 infection (sans diabetes and other established indications for SGLT2 inhibitors) may derive benefit from initiation of SGLT2 inhibitors to lessen the risk of cardiovascular and kidney disease post-COVID is yet to be investigated)46–48. The gene discussed is SLC5A2; the disease is kidney disorder.